Outlook Therapeutics, Inc.

OTLK Healthcare Biotechnology

In the quarter to June 2026, revenue fell 99.4%, EPS grew 72.7%, free cash flow fell 76.5% and total debt fell 47.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.49 0.01 −2.00%
Market cap
$121.7M
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
n/a
Altman Z
−58.86
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

118.61% 231.56% 198.37% 256.92%
ROA
(263.36%) (583.69%) (297.58%) (251.66%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
219.61% 322.56% 339.04% 1,109.13%
Average Days of Receivables
69.32 6.90 2,980.27 (515.83)
Free Cash Flow per Share
(1.49) (0.93) (0.57) (0.41)
Free Cash Flow
(51.83) (55.80) (47.05) (56.15)
Other line items

Show all line items

Columns are period end dates